

DAFTAR PUSTAKA

- Abd Ellah, N.H., Abdel-Aleem, J.A., Abdo, M.N., Abou-Ghadir, O.F., Zahran, K.M. and Hetta, H.F. (2019) 'Efficacy of ketoconazole gel-flakes in treatment of vaginal candidiasis: Formulation, in vitro and clinical evaluation.', *International journal of pharmaceuticals*, 567, p. 118472. Available at: <https://doi.org/10.1016/j.ijpharm.2019.118472>.
- Ahmed, V.A. and Goli, D. (2018) 'Development and characterization of in situ gel of xanthan gum for ophthalmic formulation containing brimonidine tartrate', *Asian Journal of Pharmaceutical and Clinical Research*, 11(7), pp. 277–284. Available at: <https://doi.org/10.22159/ajpcr.2018.v11i7.25221>.
- Aklilu, A., Bitew, A., Dessie, W., Hailu, E., Mamuye, Y. and Woldemariam, M. (2018) 'Prevalence and Drug Susceptibility Pattern of Bacterial Pathogens from Ocular Infection in St . Paul ' s Hospital Millennium Medical College , Ethiopia', *Journal of Bacteriology and Mycology*, 5(8), p. 1085.
- Allen J.R., L.V., and A.H.C. (2014) *Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. 10 th ed* Lippincott Williams and Wilkins, a Wolters Kluwer business. Philadelphia. 10th edn.
- Andersson, H., Hjærtstam, J., Stading, M., von Corswant, C. and Larsson, A. (2013) 'Effects of molecular weight on permeability and microstructure of mixed ethyl-hydroxypropyl-cellulose films.', *European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences*, 48(1–2), pp. 240–248. Available at: <https://doi.org/10.1016/j.ejps.2012.11.003>.
- Austin, A., Lietman, T. and Rose-Nussbaumer, J. (2017) 'Update on the Management of Infectious Keratitis.', *Ophthalmology*, 124(11), pp. 1678–1689. Available at: <https://doi.org/10.1016/j.ophtha.2017.05.012>.
- Avadi, M.R., Sadeghi, A.M.M., Mohammadpour, N., Abedin, S., Atyabi, F., Dinarvand, R. and Rafiee-Tehrani, M. (2010) 'Preparation and characterization of insulin nanoparticles using chitosan and Arabic gum with ionic gelation method', *Nanomedicine: Nanotechnology, Biology and Medicine*, 6(1), pp. 58–63. Available at: <https://doi.org/https://doi.org/10.1016/j.nano.2009.04.007>.
- Bale, S., Khurana, A., Reddy, A.S.S., Singh, M. and Godugu, C. (2016) 'Overview on Therapeutic Applications of Microparticulate Drug

- Delivery Systems.', *Critical reviews in therapeutic drug carrier systems*, 33(4), pp. 309–361. Available at: <https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2016015798>.
- Campoli-Richards, D.M., Monk, J.P., Price, A., Benfield, P., Todd, P.A. and Ward, A. (1988) 'Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.', *Drugs*, 35(4), pp. 373–447. Available at: <https://doi.org/10.2165/00003495-198835040-00003>.
- Chella, N., Yada, K.K. and Vempati, R. (2010) 'Preparation and evaluation of ethyl cellulose microspheres containing diclofenac Sodium by novel W/O/O emulsion method', *Journal of Pharmaceutical Sciences and Research*, 2(12), pp. 884–888.
- Chen, H., Jin, Y., Wang, J., Wang, Y., Jiang, W., Dai, H., Pang, S., Lei, L., Ji, J. and Wang, B. (2018) 'Design of smart targeted and responsive drug delivery systems with enhanced antibacterial properties', *Nanoscale*, 10(45), pp. 20946–20962. Available at: <https://doi.org/10.1039/C8NR07146B>.
- Dharmayanti, I.G.A.M.P. and Sukrama, D.M. (2019) 'Karakteristik Bakteri Pseudomonas Aeruginosa dan Pola Kepekannya Terhadap Antibiotik di Intensive Care Unit (ICU) RSUP', *E-Jurnal Medika*, 8(4), p. 13952303.
- Dhaval, M., Devani, J., Parmar, R., Soniwala, M.M. and Chavda, J. (2020) 'Formulation and optimization of microemulsion based sparfloxacin in-situ gel for ocular delivery: In vitro and ex vivo characterization', *Journal of Drug Delivery Science and Technology*, 55, p. 101373. Available at: <https://doi.org/https://doi.org/10.1016/j.jddst.2019.101373>.
- Elsahn, A., del Mar Cendra, M., Humbert, M.V., Christodoulides, M., Dua, H. and Hossain, P. (2020) 'Pseudomonas aeruginosa host-pathogen interactions in human corneal infection models', *Journal of EuCornea*, 7, pp. 8–16. Available at: <https://doi.org/https://doi.org/10.1016/j.xjec.2020.02.002>.
- Ferreira, I.S., Bettencourt, A.F., Gonçalves, L.M.D., Kasper, S., Bétrisey, B., Kikhney, J., Moter, A., Trampuz, A. and Almeida, A.J. (2015) 'Activity of daptomycin- and vancomycin-loaded poly-epsilon-caprolactone microparticles against mature staphylococcal biofilms.', *International journal of nanomedicine*, 10, pp. 4351–4366. Available at: <https://doi.org/10.2147/IJN.S84108>.
- Gao, P., Nie, X., Zou, M., Shi, Y. and Cheng, G. (2011) 'Recent advances

- in materials for extended-release antibiotic delivery system.', *The Journal of antibiotics*, 64(9), pp. 625–634. Available at: <https://doi.org/10.1038/ja.2011.58>.
- Gowda D.V. Mohammed S. Khan, Venkatesh M.P, Sowjanya A.S., S.H.. (2010) 'Preparation and Evaluation of HPMC and Eudragit Microparticles loaded with Diltiazem Hydrochloride for Controlled Release.', *Scholars Research Library*, 2(5), pp. 387–398.
- Gupta, C., Juyal, V. and Nagaich, U. (2018) 'Formulation and optimization of thermosensitive in-situ gel of moxifloxacin hydrochloride for ocular drug delivery', *International Journal of Applied Pharmaceutics*, 10(3), pp. 123–130. Available at: <https://doi.org/10.22159/ijap.2018v10i3.25083>.
- Güven, U.M., Berkman, M.S., Şenel, B. and Yazan, Y. (2019) 'in Situ Gelling Systems for Ocular Allergy'.
- Hasanah, S. (2009) *Optimasi Pembuatan Mikrosfer Polipaduan Poli Asam Laktat dengan Polikaprolakton*. IPB.
- Insani, M.L., Adioka, G.M., Artini, I. and Agung Nova Mahendra (2017) 'Karakteristik dan Manajemen Konjungtivitis Pasien Rawat Jalan di Rumah Sakit Indera Denpasar Periode Januari-April 2014', *E-Jurnal Medika*, 6(7), pp. 1–6.
- Jain D., Kumar V., Singh S., Mullertz A., S.B.D. (2016) 'Newer Trends in situ Gelling Systems For Controlled Ocular Drug Delivery', *Journal of Analytical & Pharmaceutical Research*, 2(3), pp. 1–16.
- Jones, D.S. (2008) *Pharmaceutics - Dosage Form and Design*. Pharmaceutical Press (FASTtrack Pharmacy Series). Available at: <https://books.google.co.id/books?id=F4mIGgAACAAJ>.
- Kalita, S., Devi, B., Kandimalla, R., Sharma, K.K., Sharma, A., Kalita, K., Kataki, A.C. and Kotoky, J. (2015) 'Chloramphenicol encapsulated in poly-ε-caprolactone-pluronic composite: Nanoparticles for treatment of MRSA-infected burn wounds', *International Journal of Nanomedicine*, 10(June 2017), pp. 2971–2984. Available at: <https://doi.org/10.2147/IJN.S75023>.
- Al Khateb, K., Ozhmukhametova, E.K., Mussin, M.N., Seilkhanov, S.K., Rakhypbekov, T.K., Lau, W.M. and Khutoryanskiy, V. V. (2016) 'In situ gelling systems based on Pluronic F127/Pluronic F68 formulations for ocular drug delivery', *International Journal of Pharmaceutics*, 502(1–2), pp. 70–79. Available at: <https://doi.org/10.1016/j.ijpharm.2016.02.027>.

- Khattab, A., Marzok, S. and Ibrahim, M. (2019) 'Development of optimized mucoadhesive thermosensitive pluronic based in situ gel for controlled delivery of Latanoprost: Antiglaucoma efficacy and stability approaches', *Journal of Drug Delivery Science and Technology*, 53, p. 101134. Available at: <https://doi.org/https://doi.org/10.1016/j.jddst.2019.101134>.
- Kohane, D.S. (2007) 'Microparticles and nanoparticles for drug delivery', *Biotechnology and Bioengineering*, 96(2), pp. 203–209. Available at: <https://doi.org/https://doi.org/10.1002/bit.21301>.
- Lace, R., Doherty, K.G., Dutta, D., Willcox, M.D.P. and Williams, R.L. (2020) 'Poly- ϵ -Lysine or Mel4 Antimicrobial Surface Modification on a Novel Peptide Hydrogel Bandage Contact Lens', *Advanced Materials Interfaces*, 7(21), pp. 6–11. Available at: <https://doi.org/10.1002/admi.202001232>.
- Liu, Q. and Wang, Y. (2009) 'Development of an ex vivo method for evaluation of precorneal residence of topical ophthalmic formulations.', *AAPS PharmSciTech*, 10(3), pp. 796–805. Available at: <https://doi.org/10.1208/s12249-009-9266-6>.
- M A Fathalla, Z., Vangala, A., Longman, M., Khaled, K.A., Hussein, A.K., El-Garhy, O.H. and Alany, R.G. (2017) 'Poloxamer-based thermoresponsive ketorolac tromethamine in situ gel preparations: Design, characterisation, toxicity and transcorneal permeation studies.', *European journal of pharmaceuticals and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.*, 114, pp. 119–134. Available at: <https://doi.org/10.1016/j.ejpb.2017.01.008>.
- Majeed, A. and Khan, N.A. (2019) 'Journal of Drug Delivery and Therapeutics Ocular in situ gel: An overview', *Journal of Drug Delivery and Therapeutics*, 9(1), pp. 337–347.
- Mir, M., Ahmed, N., Permana, A.D., Rodgers, A.M., Donnelly, Ryan F and Rehman, A.U. (2019) 'Enhancement in Site-Specific Delivery of Carvacrol against Methicillin Resistant Staphylococcus aureus Induced Skin Infections Using Enzyme Responsive Nanoparticles: A Proof of Concept Study.', *Pharmaceutics*, 11(11). Available at: <https://doi.org/10.3390/pharmaceutics11110606>.
- Mir, M., Ahmed, N., Permana, A.D., Rodgers, A.M., Donnelly, Ryan F. and Rehman, A.U. (2019) 'Enhancement in site-specific delivery of carvacrol against methicillin resistant staphylococcus aureus induced skin infections using enzyme responsive nanoparticles: A proof of concept study', *Pharmaceutics*, 11(11). Available at:

<https://doi.org/10.3390/pharmaceutics11110606>.

- Mohanty, D., Simharaju, N., Haque, M.A., Sahoo, C.K., Telangana, H., Telangana, H., Telangana, H. and Telangana, H. (2018) 'Review Article A Review on in situ Gel: A Novel Drug Delivery System', *International Journal of Pharmaceutical Sciences Review and Research*, 50(25), pp. 175–181.
- Morsi, N., Ghorab, D., Refai, H. and Teba, H. (2016) 'Ketorolac tromethamine loaded nanodispersion incorporated into thermosensitive in situ gel for prolonged ocular delivery', *International Journal of Pharmaceutics*, 506(1–2), pp. 57–67. Available at: <https://doi.org/10.1016/j.ijpharm.2016.04.021>.
- Muhaimin (2013) 'Study of microparticle preparation by the solvent evaporation method using focused beam reflectance measurement (FBRM)', in.
- Nadal, J.M., Dos Anjos Camargo, G., Novatski, A., Macenhan, W.R., Dias, D.T., Barboza, F.M., Lyra, A., Roik, J.R., Padilha de Paula, J., Somer, A. and Farago, P.V. (2019) 'Adapalene-loaded poly(ϵ -caprolactone) microparticles: Physicochemical characterization and in vitro penetration by photoacoustic spectroscopy.', *PloS one*, 14(3), p. e0213625. Available at: <https://doi.org/10.1371/journal.pone.0213625>.
- Parida, K., Panda, S., Ramanan, P., Roy, H., Manickam, M., Talwar, P. (2013) 'Microparticles Based Drug Delivery System: Preparation and Application in Cancer Therapeutics.', *International Journal Archive of Applied Science and Technology*, 4.
- Parikh, S.K., Patel, A.D., Dave, J.B., Patel, C.N. and Sen, D.J. (2011) 'Development and validation of UV spectrophotometric method for estimation of Itraconazole bulk drug and pharmaceutical formulation', *International Journal of Drug Development and Research*, 3(2), pp. 324–328.
- Permana, Andi Dian; Anjani K.Q., Utomo E., Zanutto-Volpe F., Paredes ., Evary Y.M., Mardikasari A.S., Pratama R.M., Tuany N.I., D.F.R. (2021) 'Selective Delivery of Silver Nanoparticles For Improved Treatment of Biofilm Skin Infection Using Bacteria-Responsive Microparticles Loaded Into Dissolving Microneedles', *Materials Science and Engineering: C*, 120, p. 111786.
- Permana, A.D., Mir, M., Utomo, E. and Donnelly, R.F. (2020) 'Bacterially sensitive nanoparticle-based dissolving microneedles of doxycycline for enhanced treatment of bacterial biofilm skin

infection: A proof of concept study.', *International journal of pharmaceuticals*: X, 2, p. 100047. Available at: <https://doi.org/10.1016/j.ijpx.2020.100047>.

- Permana, A.D., Utami, R.N., Layadi, P., Himawan, A., Juniarti, N., Anjani, Q.K., Utomo, E., Mardikasari, S.A., Arjuna, A. and Donnelly, R.F. (2021) 'Thermosensitive and mucoadhesive in situ ocular gel for effective local delivery and antifungal activity of itraconazole nanocrystal in the treatment of fungal keratitis', *International Journal of Pharmaceutics*, 602, p. 120623. Available at: <https://doi.org/https://doi.org/10.1016/j.ijpharm.2021.120623>.
- Permana, A.D., Utomo, E., Pratama, M.R., Amir, M.N., Anjani, Q.K., Mardikasari, S.A., Sumarheni, S., Himawan, A., Arjuna, A., Usmanengsi, U. and Donnelly, R.F. (2021) 'Bioadhesive-Thermosensitive In Situ Vaginal Gel of the Gel Flake-Solid Dispersion of Itraconazole for Enhanced Antifungal Activity in the Treatment of Vaginal Candidiasis.', *ACS applied materials & interfaces*, 13(15), pp. 18128–18141. Available at: <https://doi.org/10.1021/acsami.1c03422>.
- Rijal, Muh, Agus, S., Aga, M. and Retno. Sari (2010) 'Theophyllin, Chitosan, Tripolyphosphate, Microparticle, Emulsification Ionic Gelation', 8(2), pp. 28–33.
- Rowe R.C., Sheskey, P.J., and Quinn, M.E. (2009) *Handbook Of Pharmaceutical Excipients*. 6th edn. The Pharmaceutical Press. London.
- Russo, E. and Villa, C. (2019) 'Poloxamer Hydrogels for Biomedical Applications.', *Pharmaceutics*, 11(12). Available at: <https://doi.org/10.3390/pharmaceutics11120671>.
- Sarada, K., Firoz, S., Padmini, K. (2015) 'In-situ gelling system: A review', *Journal of Chemical and Pharmaceutical Research*, 5, pp. 76–90.
- Singh, R.P., sarju, N., Sharma, A., Singh, S.G. and Sanket, K. (2011) 'Microchip for drug delivery system: A review', *Journal of Applied Pharmaceutical Science*, 1(4), pp. 07–11.
- Siswandono (2008) *Kimia Medisinal ed 2*. Surabaya. Airlangga University Press. Airlangga University Press.
- Soliman, K.A., Ullah, K., Shah, A., Jones, D.S. and Singh, T.R.R. (2019) 'Poloxamer-based in situ gelling thermoresponsive systems for ocular drug delivery applications.', *Drug discovery today*, 24(8), pp. 1575–1586. Available at:

<https://doi.org/10.1016/j.drudis.2019.05.036>.

Sri Rahayu Pertiwi (2017) *Sifat Mekanik dan Morfologi Biokomposit Polikaprolakton (PCL)/ Pati Sukun (Artocarpusaltilis) Termodifikasi*. Institusi Universitas Sumatera Utara.

Sweetman, C., S. (2009) *Martindale: The Complete Drug Reference. English: 36th ed. London; Chicago: Pharmaceutical Press. English:36. London; Chicago: Pharmaceutical Press.*

Tekade, R.K. (2019) *Drug delivery systems, Drug Delivery Systems*. Available at: <https://doi.org/10.1016/C2017-0-01074-1>.

Troy, D. (2005) *Remington The Science and Practice of Pharmacy, 21st ed. Lippincott Williams & Wilkins, a Wolters Kluwer Company, Philadelphia.*

Ubani-Ukoma, U., Gibson, D., Schultz, G., Silva, B.O. and Chauhan, A. (2019) 'Evaluating the potential of drug eluting contact lenses for treatment of bacterial keratitis using an ex vivo corneal model.', *International journal of pharmaceutics*, 565, pp. 499–508. Available at: <https://doi.org/10.1016/j.ijpharm.2019.05.031>.

Ung, L., Bispo, P.J.M., Shanbhag, S.S., Gilmore, M.S. and Chodosh, J. (2019) 'The persistent dilemma of microbial keratitis: Global burden, diagnosis, and antimicrobial resistance.', *Survey of ophthalmology*, 64(3), pp. 255–271. Available at: <https://doi.org/10.1016/j.survophthal.2018.12.003>.

Vasconcellos, F.C., Goulart, G.A.S. and Beppu, M.M. (2011) 'Production and characterization of chitosan microparticles containing papain for controlled release applications', *Powder Technology*, 205(1), pp. 65–70. Available at: <https://doi.org/https://doi.org/10.1016/j.powtec.2010.08.066>.

Vilos, C. and Velasquez, L.A. (2012) 'Therapeutic Strategies Based on Polymeric Microparticles', *Journal of Biomedicine and Biotechnology*. Edited by S. Ferrone, 2012, p. 672760. Available at: <https://doi.org/10.1155/2012/672760>.

Weerakody, R., Fagan, P. and Kosaraju, S.L. (2008) 'Chitosan microspheres for encapsulation of alpha-lipoic acid.', *International journal of pharmaceutics*, 357(1–2), pp. 213–218. Available at: <https://doi.org/10.1016/j.ijpharm.2008.02.019>.


Wu, Y., Liu, Y., Li, X., Kebebe, D., Zhang, B., Ren, J., Lu, J., Li, J., Du, S. and Liu, Z. (2019) 'Research progress of in-situ gelling ophthalmic

drug delivery system.', *Asian journal of pharmaceutical sciences*, 14(1), pp. 1–15. Available at: <https://doi.org/10.1016/j.ajps.2018.04.008>.


Xiong, M.-H., Bao, Y., Yang, X.-Z., Wang, Y.-C., Sun, B. and Wang, J. (2012) 'Lipase-Sensitive Polymeric Triple-Layered Nanogel for "On-Demand" Drug Delivery', *Journal of the American Chemical Society*, 134(9), pp. 4355–4362. Available at: <https://doi.org/10.1021/ja211279u>.

LAMPIRAN

Lampiran 1. Skema kerja penelitian




Lampiran 2. Panjang gelombang maksimum dan kurva baku siprofloksasin



Gambar 20. Panjang gelombang maksimum siprofloksasin dalam metanol

Lampiran 3. Tabel hasil pengukuran serapan CPX dalam metanol untuk pembuatan kurva baku

Konsentrasi (bpj)	Serapan			Rata-rata	SD
	Replikasi 1	Replikasi 2	Replikasi 3		
2,5	0,071	0,074	0,076	0,07	0,00
5	0,139	0,141	0,144	0,14	0,00
10	0,274	0,276	0,279	0,27	0,00
20	0,506	0,509	0,601	0,53	0,05
40	0,908	0,911	0,911	0,91	0,00



Gambar 131. Kurva baku siprofloksasin dalam metanol

Lampiran 4. Tabel Efisiensi penjerapan

Formula	Replikasi	y	hasil (ug/ml)	Hasil (ug/ml) x fp	% Lepas	% Terjerap	Rata-rata	SD
F1	1	0,291	13,922	139,226	55,690	44,309	44,446	0,238
	2	0,289	13,819	138,195	55,278	44,721		
	3	0,291	13,922	139,226	55,690	44,309		
F2	1	0,218	10,159	101,597	40,639	59,360	59,429	0,119
	2	0,218	10,159	101,597	40,639	59,360		
	3	0,217	10,108	101,082	40,432	59,567		
F3	1	0,172	7,788	77,886	31,154	68,845	68,639	0,545
	2	0,171	7,737	77,371	30,948	69,051		
	3	0,176	7,994	79,948	31,979	68,020		
F4	1	0,103	4,231	42,319	16,927	83,072	83,140	0,314
	2	0,101	4,128	41,288	16,515	83,484		
	3	0,104	4,283	42,835	17,134	82,865		
F5	1	0,114	4,798	47,989	19,195	80,804	80,666	0,238
	2	0,114	4,798	47,989	19,195	80,804		
	3	0,116	4,902	49,020	19,608	80,391		

Lampiran 4.1. Perhitungan Efisiensi penyerapan dan *drug loading*

- Contoh perhitungan kadar senyawa mikropartikel yang terjerap

$$\begin{aligned} \bullet \text{F1} &= \frac{\text{Obat yang terjerap (mg)}}{\text{Jumlah obat teoritis (mg)}} \times 100\% \\ &= \frac{\text{Nilai rata-rata}}{3} \\ &= \frac{44,30}{3} = 14,76 = \frac{14,76}{40} \times 100 = 36,9\% \end{aligned}$$

- Contoh perhitungan *drug loading*

$$\text{F1} = \frac{\text{Obat yang terjerap (mg)}}{\text{Jumlah obat teoritis+polimer}} \times 100\%$$

$$\text{Jadi} = \frac{36,9}{80} \times 100\% = 46,12\%$$

Lampiran 4.2. Hasil uji viskositas

Lampiran 4.2.1. Uji viskositas suhu (4°C)

Replikasi	F1 (cPs)	F2 (cPs)	F3 (cPs)	F4 (cPs)
1	100	60	100	60
2	100	60	80	60
3	80	60	100	60
Rata-rata	93,33	60,00	93,33	60,00
SD	11,55	0	11,55	0

Lampiran 4.2.1. Uji viskositas suhu (25°C)

Replikasi	F1 (cPs)	F2 (cPs)	F3 (cPs)	F4 (cPs)
1	700	300	600	300
2	600	200	600	200
3	600	300	600	200
Rata-rata	633,33	267,67	600,00	233,33
SD	57,73	57,73	0	57,73

Lampiran 4.2.3. Uji viskositas suhu (37°C)

Replikasi	F1 (cPs)	F2 (cPs)	F3 (cPs)	F4 (cPs)
1	28000	20000	28000	8000
2	25600	16000	28000	8000
3	25600	16000	29600	12000
Rata-rata	26.400,00	17.333,33	28.533,33	9.333,33
SD	1.385,64	2.309,40	923,76	2.309,40

Lampiran 4.3. Tabel uji permeasi

Formula F1

Jam ke	Serapan	Konsentrasi ($\mu\text{g/ml}$)	Konsentrasi dalam 28 (μg)	Faktor koreksi	MP Gel permeasi (μg)	Permeasi (mg)	Rata-rata	SD
0,25	0,117	4,954	138,70	0	138,70	13,87	14,35	0,42
	0,122	5,211	145,92	0	145,92	14,59		
	0,122	5,211	145,92	0	145,92	14,59		
0,5	0,157	7,015	196,43	0,004	201,39	20,14	20,59	0,45
	0,16	7,17	200,76	0,005	205,97	20,60		
	0,163	7,325	205,09	0,005	210,30	21,03		
0,75	0,188	8,613	241,18	0,011	253,14	25,31	25,64	0,32
	0,19	8,716	244,06	0,012	256,44	25,64		
	0,192	8,82	246,95	0,012	259,48	25,95		
1	0,192	8,82	246,95	0,020	267,53	26,75	26,99	0,26
	0,193	8,871	248,39	0,021	269,49	26,95		
	0,195	8,974	251,28	0,021	272,63	27,26		
2	0,203	9,387	262,82	0,029	292,23	29,22	29,95	0,65
	0,209	9,969	271,48	0,029	301,45	30,15		
	0,211	9,799	274,37	0,030	304,70	30,47		
3	0,226	10,572	296,02	0,038	334,81	33,48	33,55	0,07
	0,226	10,572	296,02	0,039	335,69	33,57		
	0,226	10,572	296,02	0,040	336,15	33,61		
4	0,229	10,727	300,35	0,049	349,71	34,97	35,05	0,07
	0,229	10,727	300,35	0,050	350,59	35,06		
	0,229	10,727	300,35	0,050	351,05	35,11		
5	0,25	11,809	330,66	0,060	390,75	39,07	39,44	0,36
	0,252	11,912	333,55	0,060	394,51	39,45		
	0,254	12,015	336,43	0,061	397,86	39,79		

	0,256	12,119	339,32	0,071	411,22	41,12		
6	0,258	12,222	342,21	0,072	415,08	41,51	41,59	0,52
	0,262	12,428	347,98	0,073	421,42	42,14		
	0,262	12,428	347,98	0,084	431,99	43,20		
7	0,266	12,634	353,75	0,085	438,85	43,89	43,83	0,60
	0,269	12,789	358,08	0,085	443,95	44,40		
	0,264	12,531	350,87	0,096	447,31	44,73		
8	0,268	12,737	356,64	0,097	454,37	45,44	45,38	0,62
	0,271	12,892	360,97	0,098	459,63	45,96		

Formula F2

Jam ke	Serapan	Konsentrasi (µg/ml)	Konsentrasi dalam 28 (µg/ml)	Faktor koreksi	MP Gel permeasi (µg)	Permeasi (mg)	Rata-rata	SD
	0,134	5,83	163,24	0	163,24	16,32		
0,25	0,139	6,088	170,45	0	170,45	17,05	17,00	0,65
	0,143	6,294	176,23	0	176,23	17,62		
	0,143	6,294	176,23	0,005	182,06	18,21		
0,5	0,147	6,500	182,00	0,006	188,09	18,81	18,86	0,67
	0,152	6,758	189,22	0,006	195,51	19,55		
	0,168	7,582	212,31	0,012	224,43	22,44		
0,75	0,173	7,840	219,53	0,012	232,11	23,21	23,12	0,63
	0,176	7,995	223,86	0,013	236,91	23,69		
	0,275	13,098	366,74	0,019	386,45	38,64		
1	0,279	13,304	372,52	0,020	392,94	39,29	39,19	0,51
	0,281	13,407	375,40	0,021	396,45	39,64		
	0,3	14,387	402,82	0,032	435,63	43,56		
2	0,306	14,696	411,48	0,033	445,22	44,52	44,37	0,74
	0,309	14,851	415,81	0,034	450,27	45,03		

	0,312	15,005	420,14	0,047	467,34	46,73		
3	0,319	15,366	430,25	0,048	478,68	47,87	47,66	0,85
	0,322	15,521	434,58	0,049	483,88	48,39		
	0,343	16,603	464,89	0,062	527,08	52,71		
4	0,346	16,758	469,22	0,063	533,01	53,30	53,19	0,43
	0,347	16,809	470,66	0,064	535,48	53,55		
	0,384	18,716	524,06	0,078	602,86	60,29		
5	0,389	18,974	531,28	0,080	611,83	61,18	61,06	0,73
	0,392	19,129	535,61	0,081	617,24	61,72		
	0,432	21,191	593,34	0,097	690,86	69,09		
6	0,437	21,448	600,56	0,099	700,08	70,01	69,79	0,62
	0,438	21,5	602,00	0,100	702,76	70,28		
	0,467	22,995	643,86	0,118	762,56	76,26		
7	0,473	23,304	652,52	0,120	773,49	77,35	77,08	0,72
	0,474	23,356	653,96	0,122	776,22	77,62		
	0,523	25,881	724,68	0,141	866,38	86,64		
8	0,528	26,139	731,90	0,144	876,18	87,62	87,38	0,66
	0,529	26,191	733,34	0,145	878,96	87,90		

Formula 3

Jam ke	Serapan	Konsentrasi (µg/ml)	Konsentrasi dalam 28 (µg/ml)	Faktor koreksi	MP Gel permeasi (µg)	Permeasi (mg)	Rata-rata	SD
	0,149	6,603	184,89	0	184,89	18,49		
0,25	0,153	6,809	190,66	0	190,66	19,07	18,97	0,44
	0,155	6,912	193,55	0	193,55	19,35		
	0,146	6,448	180,56	0,006	187,16	18,72		
0,5	0,149	6,603	184,89	0,006	191,70	19,17	19,17	0,45
	0,152	6,758	189,22	0,006	196,13	19,61		

	0,3	14,387	402,82	0,013	415,88	41,59		
0,75	0,304	14,593	408,60	0,013	422,01	42,20	42,25	0,68
	0,309	14,851	415,81	0,013	429,48	42,95		
	0,332	16,036	449,01	0,027	476,45	47,64		
1	0,335	16,191	453,34	0,028	481,35	48,13	50,59	4,68
	0,389	18,974	531,28	0,028	559,80	55,98		
	0,396	19,335	541,38	0,043	584,86	58,49		
2	0,403	19,696	551,48	0,044	595,68	59,57	62,25	5,61
	0,464	22,84	639,53	0,047	687,02	68,70		
	0,466	22,943	642,41	0,062	705,22	70,52		
3	0,471	23,201	649,63	0,063	713,52	71,35	70,95	0,42
	0,464	22,84	639,53	0,070	709,86	70,99		
	0,476	23,459	656,85	0,085	742,60	74,26		
4	0,48	23,665	662,62	0,087	749,71	74,97	74,94	0,66
	0,48	23,665	662,62	0,093	755,79	75,58		
	0,489	24,129	675,61	0,109	784,82	78,48		
5	0,493	24,335	681,38	0,110	792,14	79,21	78,69	0,46
	0,483	23,82	666,95	0,116	783,79	78,38		
	0,485	23,923	669,84	0,133	803,18	80,32		
6	0,49	24,18	677,05	0,135	812,14	81,21	81,10	0,73
	0,49	24,18	677,05	0,140	817,71	81,77		
	0,495	24,438	684,27	0,157	841,53	84,15		
7	0,496	24,49	685,71	0,159	844,98	84,50	85,87	2,68
	0,523	25,881	724,68	0,164	889,52	88,95		
	0,528	26,139	731,90	0,181	913,60	91,36		
8	0,523	25,881	724,68	0,183	908,44	90,84	91,25	0,36
	0,523	25,881	724,68	0,190	915,40	91,54		

Formula 4

Jam ke	Serapan	Konsentrasi (µg/ml)	Konsentrasi dalam 28 (µg/ml)	Faktor koreksi	MP Gel permeasi (µg)	Permeasi (mg)	Rata-rata	SD
0,25	0,077	2,892	80,969	0	80,969	8,10	8,63	0,51
	0,081	3,098	86,742	0	86,742	8,67		
	0,084	3,253	91,072	0	91,072	9,11		
0,5	0,126	5,418	151,691	0,002	154,582	15,46	15,81	0,31
	0,13	5,624	157,464	0,003	160,562	16,06		
	0,129	5,572	156,021	0,003	159,273	15,93		
0,75	0,22	10,263	287,361	0,008	295,670	29,57	29,93	0,33
	0,223	10,418	291,691	0,008	300,412	30,04		
	0,224	10,469	293,134	0,008	301,959	30,20		
1	0,245	11,552	323,443	0,018	342,015	34,20	34,82	0,56
	0,25	11,809	330,660	0,019	349,799	34,98		
	0,252	11,912	333,546	0,019	352,840	35,28		
2	0,27	12,84	359,526	0,030	389,649	38,96	39,51	0,47
	0,275	13,098	366,742	0,030	397,691	39,77		
	0,275	13,098	366,742	0,031	397,948	39,79		
3	0,322	15,521	434,577	0,042	477,541	47,75	48,12	0,32
	0,325	15,675	438,907	0,044	482,954	48,30		
	0,325	15,675	438,907	0,044	483,211	48,32		
4	0,424	20,778	581,794	0,058	640,278	64,03	64,50	0,41
	0,428	20,985	587,567	0,059	647,289	64,73		
	0,428	20,985	587,567	0,059	647,546	64,75		
5	0,506	25,005	700,144	0,079	779,407	77,94	78,43	0,52
	0,508	25,108	703,031	0,080	783,737	78,37		
	0,512	25,314	708,804	0,080	789,768	78,98		
6	0,532	26,242	734,784	0,104	839,052	83,91		

	0,532	26,345	737,670	0,105	843,485	84,35	84,41	0,54
	0,536	26,552	743,443	0,106	849,722	84,97		
	0,533	26,397	739,113	0,130	869,624	86,96		
7	0,539	26,706	747,773	0,132	879,933	87,99	87,72	0,66
	0,54	26,758	749,216	0,132	882,046	88,20		
	0,575	28,562	799,732	0,156	956,639	95,66		
8	0,585	29,077	814,165	0,158	973,031	97,30	96,83	1,01
	0,586	29,129	0,815608247	0,975	975,196	97,52		

Lampiran 4.4.5. Tabel uji retensi

Formula	Serapan	Konsentrasi (µg/ml)	Jumlah MP CPX terdeposisi setelah 8 jam	Retensi	Rata-rata	SD
	0,116	11,608	0,348	3,482		
F1	0,118	11,814	0,354	3,544	3,69	0,32
	0,122	12,227	0,367	4,070		
	0,135	13,567	0,407	4,070		
F2	0,139	13,979	0,419	4,194	4,19	0,12
	0,143	14,392	0,432	4,318		
	0,316	32,227	0,967	9,668		
F3	0,321	32,742	0,982	9,823	10,02	0,49
	0,346	35,320	1,060	10,596		
	0,074	7,278	0,218	2,184		
F4	0,076	7,485	0,225	2,245	2,25	0,07
	0,079	7,794	0,234	2,338		

Lampiran 5. Perhitungan Permeasi dan Retensi

• Contoh perhitungan permeasi (F3)

$$\text{Persamaan } y = 0,0222x + 0,0357$$

Serapan pada jam ke 8 = 0,528. Sehingga untuk mendapatkan konsentrasi:

$$0,528 = 0,0222x + 0,0357$$

$$X = \frac{0,528 - 0,0357}{0,0222}$$

$$X = 22,175 \mu\text{g/mL}$$

$$\begin{aligned} \text{Konsentrasi dalam 1 mL} &= 22,175 \mu\text{g/ml} \times 1 \text{ mL} \\ &= 22,175 \mu\text{g} = 0,022175 \text{ mg} \end{aligned}$$

$$\begin{aligned} \text{Konsentrasi dalam 28 mL} &= 22,175 \mu\text{g/mL} \times 28 \text{ mL} \\ &= 620,9 \mu\text{g} = 0,6209 \text{ mg} \end{aligned}$$

$$\begin{aligned} \text{Faktor koreksi} &= \frac{\text{Konsentrasi jam sebelumnya} + \text{faktor koreksi sebelumnya}}{1000} \\ &= \frac{0,495 + 0,157}{1000} \\ &= 0,000616 \text{ mg} \end{aligned}$$

$$\begin{aligned} \text{Jumlah terpermeasi} &= \text{Konsentrasi dalam 28 mL} + \text{faktor koreksi} \\ &= 0,620 \text{ mg} + 0,000616 \text{ mg} \\ &= 0,620 \text{ mg} \end{aligned}$$

• Contoh Perhitungan Retensi

$$\text{Persamaan } y = 0,0222x + 0,0357$$

Keterangan : y = Serapan

x = Konsentrasi

F3 : Replikasi 1 diperoleh serapan : 0,316 sehingga untuk mendapatkan konsentrasi :

$$x = \frac{0,316 - 0,0357}{0,0222}$$

$$x = 12,626 \mu\text{g/mL}$$

$$\text{Jumlah MP CPX yang terdeposisi} = \frac{12,626 \mu\text{g/mL}}{1000} \times 30 \text{ ml} = 0,378 \text{ mg.}$$

Lampiran 6. Data analisis statistika

Lampiran 6.1. Uji suhu gelas

ANOVA					
Gelasi					
	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	2130.250	3	710.083	852.100	.000
Within Groups	6.667	8	.833		
Total	2136.917	11			

Post Hoc Tests

Multiple Comparisons						
Dependent Variable: Gelasi						
Tukey HSD						
(I) Formula	(J) Formula	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
F1	F2	-3.66667*	.74536	.005	-6.0536	-1.2798
	F3	.33333	.74536	.968	-2.0536	2.7202
	F4	-31.66667*	.74536	.000	-34.0536	-29.2798
F2	F1	3.66667*	.74536	.005	1.2798	6.0536
	F3	4.00000*	.74536	.003	1.6131	6.3869
	F4	-28.00000*	.74536	.000	-30.3869	-25.6131
F3	F1	-.33333	.74536	.968	-2.7202	2.0536
	F2	-4.00000*	.74536	.003	-6.3869	-1.6131
	F4	-32.00000*	.74536	.000	-34.3869	-29.6131
F4	F1	31.66667*	.74536	.000	29.2798	34.0536
	F2	28.00000*	.74536	.000	25.6131	30.3869
	F3	32.00000*	.74536	.000	29.6131	34.3869

*. The mean difference is significant at the 0.05 level.

Lampiran 6.2. Uji pH

ANOVA					
pH	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	48.250	3	16.083	.970	.453
Within Groups	132.667	8	16.583		
Total	180.917	11			

Lampiran 6.3. Uji Viskositas

Lampiran 6.3.1 Viskositas suhu (4°C)

ANOVA					
viskositas	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	241666.667	3	80555.556	1.692	.201
Within Groups	952133.333	20	47606.667		
Total	1193800.000	23			

Lampiran 6.3.2. Viskositas suhu (25°C)

ANOVA					
viskositas					
	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	406666.667	3	135555.556	54.222	.000
Within Groups	20000.000	8	2500.000		
Total	426666.667	11			

Post Hoc Test

Multiple Comparisons						
Dependent Variable: viskositas						
Tukey HSD						
(I) Formula	(J) Formula	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
F1	F2	366.66667*	40.82483	.000	235.9312	497.4021
	F3	33.33333	40.82483	.845	-97.4021	164.0688
	F4	400.00000*	40.82483	.000	269.2645	530.7355
F2	F1	-366.66667*	40.82483	.000	-497.4021	-235.9312
	F3	-333.33333*	40.82483	.000	-464.0688	-202.5979
	F4	33.33333	40.82483	.845	-97.4021	164.0688
F3	F1	-33.33333	40.82483	.845	-164.0688	97.4021
	F2	333.33333*	40.82483	.000	202.5979	464.0688
	F4	366.66667*	40.82483	.000	235.9312	497.4021
F4	F1	-400.00000*	40.82483	.000	-530.7355	-269.2645
	F2	-33.33333	40.82483	.845	-164.0688	97.4021
	F3	-366.66667*	40.82483	.000	-497.4021	-235.9312

*. The mean difference is significant at the 0.05 level.

Lampiran 6.3.3. Viskositas suhu (37°C)

ANOVA					
Viskositas					
	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	702.080	3	234.027	69.651	.000
Within Groups	26.880	8	3.360		
Total	728.960	11			

Post Hoc Test

Multiple Comparisons						
Dependent Variable: Viskositas						
Tukey HSD						
(I) Formula	(J) Formula	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
F1	F2	9.06667*	1.49666	.001	4.2738	13.8595
	F3	-2.13333	1.49666	.519	-6.9262	2.6595
	F4	17.06667*	1.49666	.000	12.2738	21.8595
F2	F1	-9.06667*	1.49666	.001	-13.8595	-4.2738
	F3	-11.20000*	1.49666	.000	-15.9928	-6.4072
	F4	8.00000*	1.49666	.003	3.2072	12.7928
F3	F1	2.13333	1.49666	.519	-2.6595	6.9262
	F2	11.20000*	1.49666	.000	6.4072	15.9928
	F4	19.20000*	1.49666	.000	14.4072	23.9928
F4	F1	-17.06667*	1.49666	.000	-21.8595	-12.2738
	F2	-8.00000*	1.49666	.003	-12.7928	-3.2072
	F3	-19.20000*	1.49666	.000	-23.9928	-14.4072

*. The mean difference is significant at the 0.05 level.

Lampiran 6.3.4. Permeasi

Multiple Comparisons							
Tukey HSD							
Dependent Variable	(I) Kelompok	(J) Kelompok	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
						Lower Bound	Upper Bound
1 Jam	F1	F2	-12.2062*	1.93703	.001	-18.4092	-6.0031
		F3	-23.5979*	1.93703	.000	-29.8010	-17.3949
		F4	-7.8333*	1.93703	.016	-14.0364	-1.6303
	F2	F1	12.2062*	1.93703	.001	6.0031	18.4092
		F3	-11.3918*	1.93703	.002	-17.5948	-5.1887
		F4	4.3729	1.93703	.188	-1.8302	10.5759
	F3	F1	23.5979*	1.93703	.000	17.3949	29.8010
		F2	11.3918*	1.93703	.002	5.1887	17.5948
		F4	15.7646*	1.93703	.000	9.5616	21.9677
	F4	F1	7.8333*	1.93703	.016	1.6303	14.0364

		F2	-4.3729	1.93703	.188	-10.5759	1.8302
		F3	-15.7646*	1.93703	.000	-21.9677	-9.5616
2 Jam	F1	F2	-14.4244*	2.33420	.001	-21.8993	-6.9495
		F3	-32.3058*	2.33420	.000	-39.7808	-24.8309
		F4	-9.5636*	2.33420	.015	-17.0385	-2.0887
	F2	F1	14.4244*	2.33420	.001	6.9495	21.8993
		F3	-17.8814*	2.33420	.000	-25.3564	-10.4065
		F4	4.8608	2.33420	.237	-2.6141	12.3357
	F3	F1	32.3058*	2.33420	.000	24.8309	39.7808
		F2	17.8814*	2.33420	.000	10.4065	25.3564
		F4	22.7423*	2.33420	.000	15.2673	30.2172
	F4	F1	9.5636*	2.33420	.015	2.0887	17.0385
		F2	-4.8608	2.33420	.237	-12.3357	2.6141
		F3	-22.7423*	2.33420	.000	-30.2172	-15.2673
3 Jam	F1	F2	-14.1082*	.40742	.000	-15.4129	-12.8035
		F3	-37.3986*	.40742	.000	-38.7033	-36.0939

		F4	-14.5687*	.40742	.000	-15.8734	-13.2640
	F2	F1	14.1082*	.40742	.000	12.8035	15.4129
		F3	-23.2904*	.40742	.000	-24.5951	-21.9857
		F4	-.4605	.40742	.683	-1.7652	.8442
	F3	F1	37.3986*	.40742	.000	36.0939	38.7033
		F2	23.2904*	.40742	.000	21.9857	24.5951
		F4	22.8299*	.40742	.000	21.5252	24.1346
	F4	F1	14.5687*	.40742	.000	13.2640	15.8734
		F2	.4605	.40742	.683	-.8442	1.7652
		F3	-22.8299*	.40742	.000	-24.1346	-21.5252
4 Jam	F1	F2	-18.1409*	.36454	.000	-19.3083	-16.9735
		F3	-39.8918*	.36454	.000	-41.0591	-38.7244
		F4	-29.4588*	.36454	.000	-30.6261	-28.2914
	F2	F1	18.1409*	.36454	.000	16.9735	19.3083
		F3	-21.7509*	.36454	.000	-22.9182	-20.5835
		F4	-11.3179*	.36454	.000	-12.4853	-10.1505

	F3	F1	39.8918*	.36454	.000	38.7244	41.0591
		F2	21.7509*	.36454	.000	20.5835	22.9182
		F4	10.4330*	.36454	.000	9.2656	11.6004
	F4	F1	29.4588*	.36454	.000	28.2914	30.6261
		F2	11.3179*	.36454	.000	10.1505	12.4853
		F3	-10.4330*	.36454	.000	-11.6004	-9.2656
5 Jam	F1	F2	-21.6271*	.43442	.000	-23.0183	-20.2360
		F3	-39.2543*	.43442	.000	-40.6455	-37.8631
		F4	-38.9931*	.43442	.000	-40.3843	-37.6020
	F2	F1	21.6271*	.43442	.000	20.2360	23.0183
		F3	-17.6271*	.43442	.000	-19.0183	-16.2360
		F4	-17.3660*	.43442	.000	-18.7571	-15.9748
	F3	F1	39.2543*	.43442	.000	37.8631	40.6455
		F2	17.6271*	.43442	.000	16.2360	19.0183
		F4	.2612	.43442	.929	-1.1300	1.6523
	F4	F1	38.9931*	.43442	.000	37.6020	40.3843

		F2	17.3660*	.43442	.000	15.9748	18.7571
		F3	-.2612	.43442	.929	-1.6523	1.1300
6 Jam	F1	F2	-28.1993*	.49681	.000	-29.7903	-26.6084
		F3	-39.5103*	.49681	.000	-41.1013	-37.9194
		F4	-42.8179*	.49681	.000	-44.4088	-41.2269
	F2	F1	28.1993*	.49681	.000	26.6084	29.7903
		F3	-11.3110*	.49681	.000	-12.9020	-9.7200
		F4	-14.6186*	.49681	.000	-16.2095	-13.0276
	F3	F1	39.5103*	.49681	.000	37.9194	41.1013
		F2	11.3110*	.49681	.000	9.7200	12.9020
		F4	-3.3076*	.49681	.001	-4.8985	-1.7166
	F4	F1	42.8179*	.49681	.000	41.2269	44.4088
		F2	14.6186*	.49681	.000	13.0276	16.2095
		F3	3.3076*	.49681	.001	1.7166	4.8985
7 Jam	F1	F2	-33.2491*	1.18942	.000	-37.0581	-29.4402
		F3	-42.0412*	1.18942	.000	-45.8502	-38.2323

		F4	-43.8935*	1.18942	.000	-47.7024	-40.0845
	F2	F1	33.2491*	1.18942	.000	29.4402	37.0581
		F3	-8.7921*	1.18942	.000	-12.6010	-4.9832
		F4	-10.6443*	1.18942	.000	-14.4533	-6.8354
	F3	F1	42.0412*	1.18942	.000	38.2323	45.8502
		F2	8.7921*	1.18942	.000	4.9832	12.6010
		F4	-1.8522	1.18942	.451	-5.6612	1.9567
	F4	F1	43.8935*	1.18942	.000	40.0845	47.7024
		F2	10.6443*	1.18942	.000	6.8354	14.4533
		F3	1.8522	1.18942	.451	-1.9567	5.6612
8 Jam	F1	F2	-42.0069*	.57424	.000	-43.8458	-40.1679
		F3	-45.8711*	.57424	.000	-47.7101	-44.0322
		F4	-51.4519*	.57424	.000	-53.2908	-49.6130
	F2	F1	42.0069*	.57424	.000	40.1679	43.8458
		F3	-3.8643*	.57424	.001	-5.7032	-2.0253
		F4	-9.4450*	.57424	.000	-11.2839	-7.6061

F3	F1	45.8711*	.57424	.000	44.0322	47.7101
	F2	3.8643*	.57424	.001	2.0253	5.7032
	F4	-5.5808*	.57424	.000	-7.4197	-3.7418
F4	F1	51.4519*	.57424	.000	49.6130	53.2908
	F2	9.4450*	.57424	.000	7.6061	11.2839
	F3	5.5808*	.57424	.000	3.7418	7.4197

Based on observed means.

The error term is Mean Square (Error) = .495.

*. The mean difference is significant at the ,05 level.


Lampiran 6.3.5. Retensi

ANOVA					
Retensi					
	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	2416.999	3	805.666	512.187	.000
Within Groups	12.584	8	1.573		
Total	2429.583	11			

Multiple Comparisons						
Dependent Variable: Retensi						
Tukey HSD						
(I) Kelompok	(J) Kelompok	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
F1	F2	-2.99467	1.02404	.074	-6.2740	.2847
	F3	-30.78067*	1.02404	.000	-34.0600	-27.5013
	F4	6.23467*	1.02404	.001	2.9553	9.5140
F2	F1	2.99467	1.02404	.074	-.2847	6.2740
	F3	-27.78600*	1.02404	.000	-31.0653	-24.5067
	F4	9.22933*	1.02404	.000	5.9500	12.5087
F3	F1	30.78067*	1.02404	.000	27.5013	34.0600
	F2	27.78600*	1.02404	.000	24.5067	31.0653
	F4	37.01533*	1.02404	.000	33.7360	40.2947
F4	F1	-6.23467*	1.02404	.001	-9.5140	-2.9553
	F2	-9.22933*	1.02404	.000	-12.5087	-5.9500
	F3	-37.01533*	1.02404	.000	-40.2947	-33.7360

*. The mean difference is significant at the 0.05 level.


Lampiran 7. Dokumentasi Penelitian




Gambar 23. (a) Proses pembuatan MP, (b) Penguapan pelarut MP CPX, (c) Hasil MP CPX setelah proses sentrifus, (d) MP CPX setelah pengeringan



Gambar 24. (a) Proses pembuatan gel thermosensitive, (b) pengujian pH, (c) Pengujian viskositas



Gambar 25. (a) Proses suhu gelasi, (b) Sebelum gelasi, (c) Setelah gelasi



Gambar 26. (a) Kornea babi, (b) Aparatus difusi sel Franz, (c) Spektrofotometri